Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,848 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03449238RecruitingPhase 1/Phase 2
Pembrolizumab with focused brain radiation for breast cancer brain spread
This trial studies whether pembrolizumab (an immune therapy medicine) plus stereotactic radiosurgery (focused radiation) can better control brain metastases from breast cancer. It may help shrink or slow growth of multiple brain spots with minimal treatment to surrounding tissue.
New York, New YorkAges 19–90 - NCT03219593RecruitingPhase 2
Apatinib as first treatment for older adults with advanced stomach cancer
This trial tests a pill called apatinib as a first treatment for older adults with advanced stomach or gastroesophageal junction cancer. It might help if you cannot or do not want to have chemotherapy.
Bengbu, AnhuiAges 65 years+ - NCT03073278Recruiting
Targeted re-radiation for prostate cancer recurrence in one area
This study tests a focused radiation treatment (SBRT) to a small, clearly identified spot in the prostate for men whose prostate cancer has come back after prior external beam radiation. It may help control cancer while limiting radiation to the rest of the prostate and nearby organs.
St Leonards, New South WalesAges 18 years+ - NCT03246802Recruiting
HDR brachytherapy for prostate cancer that returned after prior radiation
This trial studies a targeted, high-dose form of radiation (HDR brachytherapy) for prostate cancer that has come back after earlier radiation treatment. It aims to treat a limited (one-area) recurrence while trying to avoid serious late side effects from repeat radiation.
Kelowna, British ColumbiaAges 45 years+ - NCT02819882Recruiting
Registry study for advanced or metastatic breast cancer
This study collects health and treatment information from people with breast cancer that cannot be fully removed by surgery or that has spread to other parts of the body. It may help researchers better understand which treatments are used and how people do over time.
Elche, AlicanteAges 18 years+ - NCT02115295RecruitingPhase 2
Venetoclax plus chemotherapy for AML, high-risk MDS, or blast CML
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
Houston, TexasAges 18–65 - NCT01371630RecruitingPhase 1/Phase 2
Inotuzumab plus chemotherapy for certain types of childhood-like leukemia
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
Houston, TexasAges 18 years+ - NCT06948084RecruitingPhase 2
New drug combo vs usual care for high-risk multiple myeloma
This trial tests whether a new combination of drugs (daratumumab and teclistamab) works better than the usual treatments for multiple myeloma that has come back or stopped responding, especially in people with a high-risk form of the disease. Participants will be randomly assigned to get either the new combo or one of the standard combos.
Coeur d'Alene, IdahoAges 18 years+ - NCT07572136RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell leukemia
This trial tests a new type of CAR T-cell therapy—a treatment that uses your own immune cells engineered to fight leukemia cells. It is designed for patients with B-cell acute lymphoblastic leukemia (ALL) that has come back or stopped responding to standard treatments, and whose leukemia cells have a specific marker called TSLPR.
Bethesda, MarylandAges 18–120 - NCT07254585RecruitingPhase 2
Study of new drug combinations for advanced head and neck cancer
This trial tests two new drug combinations for people with head and neck cancer that has come back or spread. It aims to see if these combinations are safe and work better than current options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07012044RecruitingPhase 1
Cedazuridine and decitabine after stem cell transplant for childhood leukemia
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
Birmingham, AlabamaAges Up to 21 years - NCT07744126RecruitingPhase 2
Combination drug therapy for head and neck cancer that has spread
This trial tests a new combination of two drugs (telisotuzumab adizutecan and pembrolizumab) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination can help control the cancer and to find the best dose.
Duarte, CaliforniaAges 18 years+ - NCT07463807RecruitingPhase 1/Phase 2
Comparing two drug combinations for multiple myeloma that returned quickly
This study tests a new combination of two drugs, teclistamab and pomalidomide, against the usual treatment of three drugs for multiple myeloma that has come back shortly after a standard treatment. The goal is to see if the new combination works better or is safer.
Duarte, CaliforniaAges 18 years+ - NCT06769698RecruitingPhase 2
Testing fianlimab with cemiplimab for head and neck cancer
This study compares a new combination of two drugs (fianlimab and cemiplimab) against cemiplimab alone for people with head and neck cancer that has returned or spread. It aims to see if the combination works better.
Los Angeles, CaliforniaAges 18 years+ - NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Tucson, ArizonaAges 18 years+ - NCT07711002RecruitingPhase 3
Saruparib with standard therapy for metastatic hormone-sensitive prostate cancer
This trial tests a new drug called saruparib, which may help keep prostate cancer from growing. It is for men whose cancer has spread and who have already received certain treatments. The study combines saruparib with a standard hormone therapy to see if it works better than the hormone therapy alone.
Hot Springs, ArkansasAges 18 years+ - NCT01913106RecruitingPhase 1/Phase 2
Testing valacyclovir with an added cancer gene in prostate radiation
This Phase 1/2 study tests whether adding a cancer-targeting gene therapy (HSV-tk) and the antiviral medicine valacyclovir to brachytherapy can better treat recurrent prostate cancer in the prostate area. It may help by making cancer cells more vulnerable to the treatment.
Houston, TexasAges Any age - NCT03920033Recruiting
Radiation schedule for prostate cancer PSA relapse after surgery
This trial compares two different radiation schedules to treat prostate cancer that returned based on rising PSA blood tests after prostatectomy (prostate removal). If you qualify, it may help you and your team choose a radiation approach with the goal of controlling PSA relapse.
SeoulAges 20 years+ - NCT04900558Recruiting
Study outcomes after robotic bladder removal surgery
This trial follows adults who are planning to have a robotic radical cystectomy (surgery to remove the bladder and surrounding tissue) to learn what outcomes to expect. If you choose to join and meet the basics, it may help your team compare results and improve care for future patients.
Florence, TuscanyAges 18 years+ - NCT04476485Recruiting
Predicting breast cancer recurrence after extended hormone therapy
This trial looks at factors that may predict whether hormone receptor–positive breast cancer will come back after you’ve already completed 5 years of hormone (endocrine) therapy. It may help identify who benefits most from longer treatment and follow-up.
Harbin, HeilongjiangAges 18–70 - NCT05652192RecruitingPhase 2
SBRT radiation plus chemotherapy and immunotherapy for metastatic nasopharyngeal cancer
This trial tests whether adding targeted radiation (SBRT) to chemotherapy and an immunotherapy drug can help people with metastatic nasopharyngeal cancer live longer and control tumors. It may help by combining local tumor treatment with whole-body immune support.
Hangzhou, ZhejiangAges 18–75 - NCT04519151RecruitingPhase 2
Pembrolizumab plus lenvatinib for ovarian cancer that returned
This Phase 2 trial tests whether pembrolizumab plus lenvatinib can shrink ovarian cancer that has come back after platinum chemotherapy. You may be eligible if your cancer returned after a certain “time off” from prior treatment and you meet key health and safety requirements.
Ramat GanAges 18 years+ - NCT05929365Recruiting
Test genetic marker tracking to find returning colon polyps
This study looks at stool or tissue DNA changes (called mutation analysis) plus colonoscopy findings to detect whether colon polyps come back. It may help catch recurrent colorectal lesions earlier during surveillance after a large polyp was removed.
PragueAges 18–75 - NCT05984576Recruiting
Chemo and radiation for recurrent rectal cancer after prior pelvic radiation
This study looks at combining total neoadjuvant therapy (chemotherapy and radiation) for rectal cancer that has come back in the pelvis after earlier radiation. It aims to see if this treatment approach can help control the disease and improve outcomes in patients with limited spread that can potentially be removed or treated.
RomeAges 18 years+
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,848 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.